Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO)

BACKGROUND: Patients with advanced chordoma are often treated with tyrosine kinase inhibitors without any predictive factor to guide decision. We report herein an ancillary analysis of the the Angionext phase II trial (NCT 00874874). RESULTS: From May 2011 to January 2014, 26 were sampled. The 9-mon...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Lebellec, Loic, Bertucci, François, Tresch-Bruneel, Emmanuelle, Bompas, Emmanuelle, Toiron, Yves, Camoin, Luc, Mir, Olivier, Laurence, Valerie, Clisant, Stephanie, Decoupigny, Emilie, Blay, Jean-Yves, Goncalves, Anthony, Penel, Nicolas
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342029/
https://ncbi.nlm.nih.gov/pubmed/27659533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12172
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados